MS care study for young adults
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how to improve care for young adults with relapsing-remitting MS. It focuses on people who are Black, Hispanic, or have limited income.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 29 years old.
- You have relapsing-remitting MS (RRMS).
- For some parts, you need to read English or Spanish.
- You may have had MS since childhood or as an adult, and it has been less than 8 years since diagnosis.
- You cannot have progressive MS, a recent relapse, or other major brain or mental health condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with multiple sclerosis to learn more about the disease and how it affects overall health. Researchers will collect information about your symptoms, treatments, and health outcomes over time to better understand MS and improve care.
This trial aims to develop a new care model for people with multiple sclerosis (MS). It includes patients, caregivers, and healthcare professionals to ensure the best care possible.
This study follows adults with relapsing-remitting multiple sclerosis using MRI scans and blood tests. It aims to understand how the disease behaves and what markers in blood and imaging may relate to changes over time.
This study looks at how a complementary or alternative care approach affects people living with multiple sclerosis. It may help to understand whether this type of program improves symptoms or quality of life over time.
This study follows people with multiple sclerosis over time using a smartphone app and clinic visits. It aims to better understand the disease and improve care.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.